328 related articles for article (PubMed ID: 31786361)
1. Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes.
Mantovani A; Turino T; Lando MG; Gjini K; Byrne CD; Zusi C; Ravaioli F; Colecchia A; Maffeis C; Salvagno G; Lippi G; Bonora E; Targher G
Diabetes Metab; 2020 Sep; 46(4):296-303. PubMed ID: 31786361
[TBL] [Abstract][Full Text] [Related]
2. Higher liver stiffness scores are associated with early kidney dysfunction in patients with histologically proven non-cirrhotic NAFLD.
Sun DQ; Ye FZ; Kani HT; Yang JR; Zheng KI; Zhang HY; Targher G; Byrne CD; Chen YP; Yuan WJ; Yilmaz Y; Zheng MH
Diabetes Metab; 2020 Sep; 46(4):288-295. PubMed ID: 31786360
[TBL] [Abstract][Full Text] [Related]
3. Liver fibrosis by FibroScan
Lombardi R; Airaghi L; Targher G; Serviddio G; Maffi G; Mantovani A; Maffeis C; Colecchia A; Villani R; Rinaldi L; Orsi E; Pisano G; Adinolfi LE; Fargion S; Fracanzani AL
Liver Int; 2020 Feb; 40(2):347-354. PubMed ID: 31612634
[TBL] [Abstract][Full Text] [Related]
4. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
[TBL] [Abstract][Full Text] [Related]
5. Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications.
Ciardullo S; Muraca E; Perra S; Bianconi E; Zerbini F; Oltolini A; Cannistraci R; Parmeggiani P; Manzoni G; Gastaldelli A; Lattuada G; Perseghin G
BMJ Open Diabetes Res Care; 2020 Feb; 8(1):. PubMed ID: 32049637
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study.
Cardoso CRL; Villela-Nogueira CA; Leite NC; Salles GF
Cardiovasc Diabetol; 2021 Sep; 20(1):193. PubMed ID: 34560854
[TBL] [Abstract][Full Text] [Related]
7. Associations between higher plasma ferritin and hepcidin levels with liver stiffness in patients with type 2 diabetes: An exploratory study.
Mantovani A; Csermely A; Castagna A; Antinori E; Danese E; Zusi C; Sani E; Ravaioli F; Colecchia A; Maffeis C; Valenti L; Girelli D; Targher G
Liver Int; 2023 Nov; 43(11):2434-2444. PubMed ID: 37312616
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of non-alcoholic fatty liver disease among patients with non-diabetic chronic kidney disease detected by transient elastography.
Behairy MA; Sherief AF; Hussein HA
Int Urol Nephrol; 2021 Dec; 53(12):2593-2601. PubMed ID: 33675475
[TBL] [Abstract][Full Text] [Related]
9. Significant liver fibrosis, as assessed by fibroscan, is independently associated with chronic vascular complications of type 2 diabetes: A multicenter study.
Mikolasevic I; Rahelic D; Turk-Wensween T; Ruzic A; Domislovic V; Hauser G; Matic T; Radic-Kristo D; Krznaric Z; Radic M; Filipec Kanizaj T; Martinovic M; Jerkic H; Medjimurec M; Targher G
Diabetes Res Clin Pract; 2021 Jul; 177():108884. PubMed ID: 34082054
[TBL] [Abstract][Full Text] [Related]
10. Transient elastography for the prevalence of non-alcoholic fatty liver disease in patients with type 2 diabetes: Evidence from the CORDIAL cohort study.
Alfadda AA; Sherbeeni SM; Alqutub AN; Aldosary AS; Aldaghri NM; Taylor-Robinson SD; Alqahtani SA; Gul R; Almaghamsi AM
Saudi J Gastroenterol; 2022; 28(6):426-433. PubMed ID: 35645140
[TBL] [Abstract][Full Text] [Related]
11. Non-alcoholic fatty liver disease (NAFLD) and significant hepatic fibrosis defined by non-invasive assessment in patients with type 2 diabetes.
Sobhonslidsuk A; Pulsombat A; Kaewdoung P; Petraksa S
Asian Pac J Cancer Prev; 2015; 16(5):1789-94. PubMed ID: 25773826
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of controlled attenuation parameter and liver stiffness measurement for detecting increased arterial stiffness in asymptomatic populations in China.
Yu XY; Song XX; Tong YL; Wu LY; Song ZY
Medicine (Baltimore); 2020 Nov; 99(48):e23360. PubMed ID: 33235107
[TBL] [Abstract][Full Text] [Related]
13. Clinical spectrum of non-alcoholic fatty liver disease in patients with diabetes mellitus.
Chen K; Sng WK; Quah JH; Liu J; Chong BY; Lee HK; Wang XF; Tan NC; Chang PE; Tan HC; Bee YM; Goh GBB
PLoS One; 2020; 15(8):e0236977. PubMed ID: 32822391
[TBL] [Abstract][Full Text] [Related]
14. Association between non-alcoholic fatty liver disease and impaired cardiac sympathetic/parasympathetic balance in subjects with and without type 2 diabetes-The Cooperative Health Research in South Tyrol (CHRIS)-NAFLD sub-study.
Targher G; Mantovani A; Grander C; Foco L; Motta B; Byrne CD; Pramstaller PP; Tilg H
Nutr Metab Cardiovasc Dis; 2021 Nov; 31(12):3464-3473. PubMed ID: 34627696
[TBL] [Abstract][Full Text] [Related]
15. Metabolic dysfunction-associated steatotic liver disease-related hepatic fibrosis increases risk of insulin resistance, type 2 diabetes, and chronic kidney disease.
Zhang W; Song WJ; Chen W; Pan Z; Zhang J; Fan L; Li J
Eur J Gastroenterol Hepatol; 2024 Jun; 36(6):802-810. PubMed ID: 38526946
[TBL] [Abstract][Full Text] [Related]
16. Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association.
Lee BW; Lee YH; Park CY; Rhee EJ; Lee WY; Kim NH; Choi KM; Park KG; Choi YK; Cha BS; Lee DH;
Diabetes Metab J; 2020 Jun; 44(3):382-401. PubMed ID: 32431115
[TBL] [Abstract][Full Text] [Related]
17. Elastographic parameters of liver steatosis and fibrosis predict independently the risk of incident chronic kidney disease and acute myocardial infarction in patients with type 2 diabetes mellitus.
Mikolasevic I; Domislovic V; Ruzic A; Hauser G; Rahelic D; Klobucar-Majanovic S; Krznaric Z; Dobrila-Dintinjana R; Grgurevic I; Skenderevic N; Lukic A; Targher G
J Diabetes Complications; 2022 Aug; 36(8):108226. PubMed ID: 35803839
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis.
Sagara M; Iijima T; Kase M; Kato K; Sakurai S; Tomaru T; Jojima T; Usui I; Aso Y
J Diabetes Complications; 2021 May; 35(5):107885. PubMed ID: 33602617
[TBL] [Abstract][Full Text] [Related]
19. Advanced liver fibrosis but not steatosis is independently associated with albuminuria in Chinese patients with type 2 diabetes.
Yeung MW; Wong GL; Choi KC; Luk AO; Kwok R; Shu SS; Chan AW; Lau ESH; Ma RCW; Chan HL; Chan JC; Wong VW; Kong AP
J Hepatol; 2017 Oct; ():. PubMed ID: 28989092
[TBL] [Abstract][Full Text] [Related]
20. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study.
Kwok R; Choi KC; Wong GL; Zhang Y; Chan HL; Luk AO; Shu SS; Chan AW; Yeung MW; Chan JC; Kong AP; Wong VW
Gut; 2016 Aug; 65(8):1359-68. PubMed ID: 25873639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
